OverviewSuggest Edit

Agile Therapeutics is the pharmaceutical company developing contraceptive healthcare products for women. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive patch.

In addition to Twirla, Agile is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of the Company's product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

TypePublic
Founded1997
HQPrinceton, NJ, US
Websiteagiletherapeutics.com

Latest Updates

Employees (est.) (Dec 2019)15(+16%)
Revenue (FY, 2020)$749 K
Share Price (Jun 2021)$1.5
Cybersecurity ratingAMore

Key People/Management at Agile Therapeutics

Al Altomari

Al Altomari

President & CEO & Board ofDirectors
Scott Coiante

Scott Coiante

CFO
C.Gregory Arnold

C.Gregory Arnold

Vice President of Manufacturing
Robert G.Conway

Robert G.Conway

Chief Development Officer, Vice President, Operations
Elizabeth Garner

Elizabeth Garner

Senior Vice President and Chief Medical Officer
Show more

Agile Therapeutics Office Locations

Agile Therapeutics has offices in Princeton and Brentwood
Princeton, NJ, US (HQ)
101 Poor Farm Rd
Brentwood, NY, US
1155 Long Island Ave, Edgewood
Show all (2)

Agile Therapeutics Financials and Metrics

Agile Therapeutics Revenue

Agile Therapeutics's revenue was reported to be $749 k in FY, 2020
USD

Revenue (Q1, 2021)

116.0k

Gross profit (Q1, 2021)

(1.0m)

Gross profit margin (Q1, 2021), %

(900.9%)

Net income (Q1, 2021)

(17.1m)

EBIT (Q1, 2021)

(16.2m)

Market capitalization (7-Jun-2021)

135.9m

Closing stock price (7-Jun-2021)

1.5

Cash (31-Mar-2021)

16.5m

EV

135.2m
Agile Therapeutics's current market capitalization is $135.9 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

749.0k

Cost of goods sold

282.0k

Gross profit

467.0k

Gross profit Margin, %

62%
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

116.0k

Cost of goods sold

1.2m

Gross profit

(1.0m)

Gross profit Margin, %

(901%)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

40.2m34.4m48.8m36.0m7.9m34.5m14.5m

Accounts Receivable

539.0m865.0k

Prepaid Expenses

762.0k607.0k840.0k1.4m

Inventories

100.0k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

53.5m45.7m53.9m46.4m39.4m65.5m59.2m51.7m41.7m33.9m43.8m28.3m22.5m16.9m11.6m10.6m18.4m93.9m39.4m16.5m

Accounts Receivable

322.0k

Prepaid Expenses

661.2k1.4m495.2k817.1k1.3m3.0m2.1m3.1m2.5m525.0k1.2m633.0k200.0k731.0k378.0k178.0k1.3m672.0k1.5m1.7m

Inventories

1.6m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(16.1m)(30.3m)(28.7m)(28.3m)(19.8m)(18.6m)(51.9m)

Depreciation and Amortization

12.6k18.0k19.0k23.0k23.0k163.0k276.0k

Inventories

(2.3m)(1.2m)922.0k

Accounts Payable

2.6m1.3m362.0k(2.5m)(1.2m)1.4m3.6m
Quarterly
USDQ2, 2014

Financial Leverage

1.4 x
Show all financial metrics

Agile Therapeutics Operating Metrics

FY, 2016

Patents (Foreign)

45

Patents (US)

13

Phase I Trials Products

3

Phase III Trials Products

1
Show all operating metrics

Agile Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Agile Therapeutics Online and Social Media Presence

Embed Graph

Agile Therapeutics News and Updates

Agile Therapeutics to Participate in the William Blair 41st Annual Growth Stock Conference

PRINCETON, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the company will be participating virtually in the William Blair 41st Annual Growth Stock Conference.

Agile Therapeutics to Participate in Virtual Fireside Chat as Part of the 2021 RBC Capital Markets Global Healthcare Conference

PRINCETON, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat as part of the 2021 RBC Capital Markets Global Healthcare Con…

CORRECTING AND REPLACING -- Agile Therapeutics

PRINCETON, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by Agile Therapeutics, Inc. (Nasdaq: AGRX), please note the headline should read "Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2021" instead of …

Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020

Live Conference Call and Webcast at 4:30 p.m. EDT Live Conference Call and Webcast at 4:30 p.m. EDT

Agile Therapeutics to Present at Upcoming March Investor Conferences

PRINCETON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will present at two investor conferences in March.

Agile Therapeutics Reports Fourth Quarter & Full Year 2020 Financial Results; Expands Loan Facility With Perceptive Advisors

Perceptive Advisors Increases Credit Facility to $45 million, with $25 million potentially available
Show more

Agile Therapeutics Blogs

Agile Therapeutics Reports First Quarter 2021 Financial Results

Prescription Growth Reflects Increasing Demand for Twirla Base of Prescribers Continues to Grow in First Quarter 2021 Growing Distribution Network and Marketing Efforts Expected to Drive Healthcare Provider and Consumer Engagement PRINCETON, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Agile

Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women of Differing BMI Categories at ACOG Annual Meeting

PRINCETON, N.J. , April 30, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics , Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial evaluating the safety and efficacy of Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system

Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference Content Import Mon, 01/04/2021 - 12:19 Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference January 4, 2021 …

Agile Therapeutics Reports Third Quarter 2020 Financial Results

Commercial Launch of Twirla ® Expected by Year-End 2020 $71.9 Million in Cash, Cash Equivalents, and Marketable Securities as of September 30, 2020 Management to Host Conference Call today at 4:30 PM ET PRINCETON, N.J. , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc.

Agile Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Provide Corporate and Twirla® Commercial Updates on Thursday, November 12, 2020

Agile Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Provide Corporate and Twirla® Commercial Updates on Thursday, November 12, 2020 Content Import Wed, 11/04/2020 - 07:31 Agile Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Pro…

Kimberly Whelan

Kimberly Whelan Liz.McPherson@… Thu, 10/29/2020 - 15:15 Kimberly Whelan Vice President, Sales and Market Access Ms. Whelan has been our Vice President of Sales and Market Access since December 2019. She brings over 35 years of experience …
Show more

Agile Therapeutics Frequently Asked Questions

  • When was Agile Therapeutics founded?

    Agile Therapeutics was founded in 1997.

  • Who are Agile Therapeutics key executives?

    Agile Therapeutics's key executives are Al Altomari, Scott Coiante and C.Gregory Arnold.

  • How many employees does Agile Therapeutics have?

    Agile Therapeutics has 15 employees.

  • What is Agile Therapeutics revenue?

    Latest Agile Therapeutics annual revenue is $749 k.

  • What is Agile Therapeutics revenue per employee?

    Latest Agile Therapeutics revenue per employee is $49.9 k.

  • Who are Agile Therapeutics competitors?

    Competitors of Agile Therapeutics include Ogeda, Asarina Pharma and Sebela Pharmaceuticals.

  • Where is Agile Therapeutics headquarters?

    Agile Therapeutics headquarters is located at 101 Poor Farm Rd, Princeton.

  • Where are Agile Therapeutics offices?

    Agile Therapeutics has offices in Princeton and Brentwood.

  • How many offices does Agile Therapeutics have?

    Agile Therapeutics has 2 offices.